NIC-0102

• Description:

  NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS) -induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β[1].

• UNSPSC:

  12352005

• Target:

  NOD-like Receptor (NLR) ; Proteasome

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nic-0102.html

• Purity:

  98.72

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC (C[C@@H] (B (O) O) NC ([C@@H] (NC (C1=C (C=CC=C1F) F) =O) CC2=CC=CC=C2) =O) C

• Molecular Formula:

  C21H25BF2N2O4

• Molecular Weight:

  418.24

• References & Citations:

  [1]Wu X, et al. Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity. J Med Chem. 2022 Sep 5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2806031-94-5